PharmaKB logo
Company Reports
Company Reports
Drug Reports
Drug Reports
Disease Reports
Disease Reports
Sets
Sets
Favorites
Favorites
Log in
Log in
AboutPricing
Drug ReportsVilanterol
Anoro ellipta, Relvar ellipta(vilanterol acetate)
Anoro, Anoro Ellipta, Ellipta, Laventair, Laventair Ellipta (vilanterol acetate) is a small molecule pharmaceutical. Vilanterol acetate was first approved as Breo ellipta on 2013-05-10. It has been approved in Europe to treat asthma and chronic obstructive pulmonary disease.
Download report
Favorite
Events Timeline
Commercial
Clinical
Drug
Target
Variants
Financial
Trends
Safety
Events Timeline
5D
1M
3M
6M
YTD
1Y
2Y
5Y
Max
Events
FDA approval date
EMA approval date
Patent expiration date
Study first post date
Last update post date
Start date
Primary completion date
Completion date
Results first post date
Plot placeholder
Mock data
Subscribe for the real data
Commercial
Therapeutic Areas
Therapeutic Area
MeSH
respiratory tract diseasesD012140
immune system diseasesD007154
signs and symptoms pathological conditionsD013568
Trade Name
FDA
EMA
Combinations
Anoro ellipta, Breo ellipta, Trelegy ellipta
Drug Products
FDA
EMA
New Drug Application (NDA)
New Drug Application (NDA)
Abbreviated New Drug Application (ANDA)
Abbreviated New Drug Application (ANDA)
Umeclidinium bromide
+
Vilanterol trifenatate
Tradename
Company
Number
Date
Products
ANORO ELLIPTAGSKN-203975 RX2013-12-18
1 products, RLD, RS
Fluticasone furoate
+
Vilanterol trifenatate
Tradename
Company
Number
Date
Products
BREO ELLIPTAGSKN-204275 RX2013-05-10
3 products, RLD, RS
Fluticasone furoate
+
Umeclidinium bromide
+
Vilanterol trifenatate
Tradename
Company
Number
Date
Products
TRELEGY ELLIPTAGSKN-209482 RX2017-09-18
2 products, RLD, RS
Labels
FDA
EMA
Brand Name
Status
Last Update
anoro elliptaNew Drug Application2023-06-02
Indications
FDA
EMA
Indication
Ontology
MeSH
ICD-10
obstructive sleep apneaEFO_0003918D020181G47.33
chronic bronchitis—D029481J42
pulmonary emphysema—D011656J43
allergic rhinitis perennialEFO_1001417D012221J30.89
Agency Specific
FDA
EMA
Expiration
Code
FLUTICASONE FUROATE / VILANTEROL TRIFENATATE, BREO ELLIPTA, GLAXO GRP LTD
2026-11-13PED
2026-05-13NPP, NS
Patent Expiration
Patent
Expires
Flag
FDA Information
Fluticasone Furoate / Umeclidinium Bromide / Vilanterol Trifenatate, Trelegy Ellipta, Glaxosmithkline
97507262030-11-29DP
110902942030-11-29U-3202, U-3203
87462422030-10-11DP
85342812030-03-08DP
81619682028-02-05DP
74888272027-12-18DS, DP
93333102027-10-02DP
85113042027-06-14DPU-1424, U-1476, U-1691, U-2954, U-3623
81832572025-07-27U-1476, U-2128, U-2129
74393932025-05-21DS, DPU-1401, U-1476, U-1691, U-2099, U-2100, U-2127, U-2957, U-3623
74984402025-04-27DS, DP
83095722025-04-27U-1476, U-2129
Fluticasone Furoate / Vilanterol Trifenatate, Breo Ellipta, Glaxo Grp Ltd
111167212029-02-26DPU-1401, U-1691, U-3623
ATC Codes
R: Respiratory system drugs
— R03: Drugs for obstructive airway diseases
— R03A: Adrenergics, inhalants
— R03AK: Adrenergics inhalants in combination with corticosteroids or other drugs, excl. anticholinergics
— R03AK10: Vilanterol and fluticasone furoate
— R03AL: Adrenergics in combination with anticholinergics incl. triple combinations with corticosteroids
— R03AL03: Vilanterol and umeclidinium bromide
— R03AL08: Vilanterol, umeclidinium bromide and fluticasone furoate
HCPCS
No data
Clinical
Clinical Trials
171 clinical trials
View more details
Plot placeholder
Mock data
Subscribe for the real data
Indications Phases 4
Indication
MeSH
Ontology
ICD-10
Ph 1
Ph 2
Ph 3
Ph 4
Other
Total
Chronic obstructive pulmonary diseaseD029424EFO_0000341J44.91914502312117
Lung diseasesD008171EFO_0003818J98.4274611672
AsthmaD001249EFO_0000270J451012255151
Obstructive lung diseasesD008173——14278443
Respiratory aspirationD053120EFO_1001839——172—10
Heart failureD006333EFO_0003144I50———1—1
InflammationD007249MP_0001845————1—1
Respiratory tract diseasesD012140—————1—1
Respiration disordersD012120—J00-J99———1—1
Chronic bronchitisD029481—J42———1—1
Show 1 more
Indications Phases 3
Indication
MeSH
Ontology
ICD-10
Ph 1
Ph 2
Ph 3
Ph 4
Other
Total
Non-small-cell lung carcinomaD002289————1——1
Lung neoplasmsD008175—C34.90——1——1
Cardiovascular diseasesD002318EFO_0000319I98——1——1
Mechanical ventilatorsD012122————1——1
Indications Phases 2
Indication
MeSH
Ontology
ICD-10
Ph 1
Ph 2
Ph 3
Ph 4
Other
Total
PharmacokineticsD010599———1———1
Indications Phases 1
Indication
MeSH
Ontology
ICD-10
Ph 1
Ph 2
Ph 3
Ph 4
Other
Total
Renal insufficiencyD051437—N191————1
Indications Without Phase
Indication
MeSH
Ontology
ICD-10
Ph 1
Ph 2
Ph 3
Ph 4
Other
Total
Exercise toleranceD017079——————22
DyspneaD004417—R06.0————11
Acupuncture therapyD015670——————11
Epidemiology
Epidemiological information for investigational and approved indications
View more details
Drug
General
Drug common nameVilanterol acetate
INNvilanterol
Description
Anoro, Anoro Ellipta, Ellipta, Laventair, Laventair Ellipta (vilanterol acetate) is a small molecule pharmaceutical. Vilanterol acetate was first approved as Breo ellipta on 2013-05-10. It has been approved in Europe to treat asthma and chronic obstructive pulmonary disease.
Classification
Small molecule
Drug class—
Image (chem structure or protein)Loading
Structure (InChI/SMILES or Protein Sequence)
CC(=O)O.OCc1cc([C@@H](O)CNCCCCCCOCCOCc2c(Cl)cccc2Cl)ccc1O
Identifiers
PDB—
CAS-ID503068-35-7
RxCUI—
ChEMBL IDCHEMBL1084647
ChEBI ID—
PubChem CID—
DrugBank—
UNII ID028LZY775B (ChemIDplus, GSRS)
Target
No data
Variants
No data
Financial
Revenue by drug
$
€
£
₣
Anoro ellipta – Innoviva
Plot placeholder
Mock data
Subscribe for the real data
Plot placeholder
Mock data
Subscribe for the real data
Trelegy ellipta – Innoviva
Plot placeholder
Mock data
Subscribe for the real data
Plot placeholder
Mock data
Subscribe for the real data
Tabular view
Estimated US medical usage
Vilanterol acetate
+
Umeclidinium
+
Vilanterol
+
Fluticasone
Total medical expenditures per year (USD, in millions)
Plot placeholder
Mock data
Subscribe for the real data
Number of persons purchased
Plot placeholder
Mock data
Subscribe for the real data
Number of purchases
Plot placeholder
Mock data
Subscribe for the real data
Refill frequency
Plot placeholder
Mock data
Subscribe for the real data
Price per prescription (USD)
Plot placeholder
Mock data
Subscribe for the real data
Vilanterol acetate
+
Vilanterol
+
Fluticasone
Total medical expenditures per year (USD, in millions)
Plot placeholder
Mock data
Subscribe for the real data
Number of persons purchased
Plot placeholder
Mock data
Subscribe for the real data
Number of purchases
Plot placeholder
Mock data
Subscribe for the real data
Refill frequency
Plot placeholder
Mock data
Subscribe for the real data
Price per prescription (USD)
Plot placeholder
Mock data
Subscribe for the real data
Vilanterol acetate
+
Umeclidinium
+
Vilanterol
Total medical expenditures per year (USD, in millions)
Plot placeholder
Mock data
Subscribe for the real data
Number of persons purchased
Plot placeholder
Mock data
Subscribe for the real data
Number of purchases
Plot placeholder
Mock data
Subscribe for the real data
Refill frequency
Plot placeholder
Mock data
Subscribe for the real data
Price per prescription (USD)
Plot placeholder
Mock data
Subscribe for the real data
Tabular view
Trends
No data
Safety
Black-box Warning
No Black-box warning
Adverse Events
Top Adverse Reactions
Plot placeholder
Mock data
Subscribe for the real data
64,702 adverse events reported
View more details
© 2020-2025 Collaborative Drug Discovery Inc. (CDD) | Terms of Use